Ticagrelor Medications

Ticagrelor Info

What Is Ticagrelor?

Ticagrelor is an antiplatelet medicine that belongs to a class of drugs called P2Y12 receptor antagonists. It helps keep blood platelets from sticking together, which reduces the chance of clot formation. In Hong Kong, ticagrelor is available as the branded product Brilinta and is used in the management of certain heart-related conditions.

Medications with Ticagrelor

The primary product containing ticagrelor on the Hong Kong market is Brilinta. Brilinta is supplied as oral tablets, most commonly in 90 mg strengths; a higher 180 mg tablet is also marketed for specific dosing regimens. The medication is sold under the Brilinta brand name, but generic versions of ticagrelor may become available as patents expire. Tablet forms are the usual preparation, and the drug is prescribed as part of a broader treatment plan for cardiovascular health.

What Does Ticagrelor Treat?

• Acute coronary syndrome (ACS) - including unstable angina and heart attacks (both NSTEMI and STEMI). Ticagrelor helps prevent new clots that can worsen the condition.
• Post-myocardial-infarction care - after a heart attack, the drug is used to lower the risk of another event such as a repeat heart attack or stroke.
• Patients undergoing percutaneous coronary intervention (PCI) - when a stent is placed, ticagrelor reduces the chance that the stent becomes blocked by a clot.

These uses are approved by the Hong Kong Department of Health and are reflected in the product’s labeling. Some clinicians may employ ticagrelor in other cardiovascular situations, but those applications are considered off-label and should follow local prescribing guidance.

How Ticagrelor Works

Ticagrelor stops platelets from activating and joining together by blocking a specific receptor on the platelet surface. By keeping platelets loose, the medication lessens the likelihood of clot formation in arteries that supply the heart. The effect begins relatively quickly after the tablet is taken, providing early protection during the critical period after an acute heart event.

Safety Information

Common Side Effects

• Mild shortness of breath or feeling light-headed.
• Headaches or dizziness that usually pass on their own.
• Small bruises or bleeding from the gums or nose.
• Upset stomach, nausea, or indigestion.

These reactions are generally transient and do not require medical intervention unless they persist or worsen.

Serious Reactions

• Uncontrolled or severe bleeding, such as blood in the urine, stool, or prolonged nosebleeds.
• Signs of an allergic response, including rash, swelling of the face or throat, or difficulty breathing.
• Sudden drop in blood pressure or fainting.

If any of these occur, seek emergency medical care promptly.

Who Should Be Cautious

• Individuals with a known allergy to ticagrelor or any component of Brilinta should avoid the medication.
• People with active bleeding, a history of frequent bleeding, or certain liver conditions need careful assessment before use.
• Pregnant or breastfeeding persons should discuss potential risks with a qualified health professional, as safety data are limited.

Interaction Awareness

• Drugs that affect the same metabolic pathway (CYP3A inhibitors like certain antifungals or strong inducers such as some anticonvulsants) can alter ticagrelor levels.
• Combining ticagrelor with other blood-thinning agents, including warfarin, heparin, or non-steroidal anti-inflammatory drugs (NSAIDs), may increase bleeding risk.
• Alcohol in excess can also heighten bleeding tendencies.

For a complete list of interactions, refer to the individual medication’s detailed information.

What to Know Before Using

Store Brilinta tablets at room temperature, away from moisture and direct sunlight. The usual course of treatment can range from a few months to longer periods, depending on the underlying heart condition and the physician’s plan. Always follow the specific instructions that come with the medication, as formulations and dosing schedules can differ between brand and generic versions.

Key Terms

Antiplatelet: A type of medicine that reduces the ability of blood platelets to form clots.

Acute coronary syndrome: A term covering heart-related emergencies such as unstable angina and heart attacks.

Percutaneous coronary intervention: A non-surgical procedure, often involving a stent, to open narrowed heart arteries.

Information Disclaimer

This article offers general educational information about ticagrelor as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing ticagrelor may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.